Open AccessSuccessful treatment with nivolumab for lung cancer with low expression of PD‐L1 and prominent tumor‐infiltrating B cells and immunoglobulin G
Author(s) -
Suyama Takayuki,
Fukuda Yuichi,
Soda Hiroshi,
Ogawara Daiki,
Iwasaki Keisuke,
Hara Takuya,
Yoshida Masataka,
Harada Tatsuhiko,
Umemura Asuka,
Yamaguchi Hiroyuki,
Mukae Hiroshi
Publication year - 2018
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12644
Subject(s) - nivolumab , medicine , lung cancer , antibody , lymph node , immunohistochemistry , humoral immunity , immune system , biopsy , lymph node biopsy , cancer , biomarker , immunity , lung , immunology , cancer research , oncology , pathology , immunotherapy , biology , biochemistry
Little is known about the anti‐tumor activity of humoral immunity in lung cancer patients treated with nivolumab, an immune checkpoint inhibitor. Herein, we report a case of lung cancer with 5% expression of PD‐L1, in which a partial response to nivolumab was sustained for > 7 months. Immunohistochemical analysis of the metastatic lymph node biopsy specimen showed prominent accumulation of plasma cells and immunoglobulin G. These findings suggest that pre‐existing humoral immunity may be worth considering as a candidate therapeutic biomarker of nivolumab in some lung cancer patients.